跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 3,500 条关于
“MTLE”
全部
3,500
临床试验
3,435
药物
18
机构
0
资讯
47
去年
uniQure Doses First Patient in Phase I/IIa Trial of AMT-260 for Refractory Mesial Temporal Lobe Epilepsy
11个月前
Neurona Therapeutics Receives EMA PRIME Designation for NRTX-1001 Cell Therapy in Drug-Resistant Focal Epilepsy
去年
uniQure Doses First Patient in Phase I/IIa Trial of AMT-260 for Refractory Mesial Temporal Lobe Epilepsy
去年
uniQure's Gene Therapy AMT-260 Achieves 92% Seizure Reduction in First Drug-Resistant Epilepsy Patient
去年
Neurona Therapeutics to Present at Upcoming Investor Conferences
4年前
First Patient Dosed in Groundbreaking Stem Cell Therapy Trial for Drug-Resistant Epilepsy Shows Dramatic Seizure Reduction
去年
Stem Cell-Derived Therapy Trial Enrolls First Michigan Patient for Drug-Resistant Epilepsy
去年
Neurona's NRTX-1001 Cell Therapy Advances to Phase 3 Trial for Drug-Resistant Epilepsy
去年
uniQure's AMT-130 Shows Promise in Huntington's Disease, FDA Meeting Scheduled
5个月前
UCB Acquires Neurona Therapeutics for $1.15 Billion to Advance Regenerative Cell Therapy for Drug-Resistant Epilepsy
第 1 页,共 5 页
上一页
下一页